Lavender Swirl Background


LyGenesis, Inc.

This developing technology will allow patients to regrow tissues in their own body, possibly revolutionizing the transplant market.

A spinout from University of Pittsburgh’s McGowan Institute for Regenerative Medicine, LyGenesis, Inc.’s technology enables the use of a patient’s own lymph nodes to act as bioreactors to regrow functioning ectopic organs including liver, kidney, thymus, and pancreas.

The initial target for clinical development is liver regeneration, with a focus on helping patients with end-stage liver disease (ESLD) using a hepatocyte cell therapy product implanted into periduodenal lymph nodes.

LyGenesis’ technology allows a single donated liver to act as the seed for dozens of transplants using outpatient endoscopy to engraft the cells. These allogeneic hepatocytes engraft, vascularize, and perform all of the functions typical to liver tissue, enabling them to rescue patients from ESLD.

LyGenesis’ innovative work could revolutionize the transplant market, allowing patients to potentially avoid a liver transplant, or extending the lifespan of those ineligible for a liver transplant.

Classified as a cell therapy by the FDA, LyGenesis represents a near-term, real world example of regenerative medicine. Moreover, the ability of its organogenesis platform to regenerate functioning thymus, pancreas and renal tissues opens up a broad array of potential clinical indications. Second generation therapies using gene-modified cells could help to create off-the-shelf therapies, which could reduce or eliminate the need for immune suppression.

In the News


Longevity Companies to Watch in 2021

Juvenescence and its partners – the Buck Institute for Research on Aging, Insilico Medicine, and LyGenesis – have been identified as leaders who are driving important scientific advances in the longevity field.

January 4, 2021

Read More

LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease

LyGenesis, Inc. announced that the FDA has cleared its Investigational New Drug application and a study will be conducted on the safety and efficacy of its first-in-class novel cell therapy for patients with end stage liver disease (ESLD).

December 30, 2020

Read More

LyGenesis Announces Four Peer-Reviewed Publications on its Organ Regeneration Technology

LyGenesis announces four new peer-reviewed publications highlighting its advancing technology for kidney and liver regeneration.

August 27, 2020

Read More
Contact Us
We are here to help answer any questions you might have.